Abstract 2939: Discovery and synthesis of highly potent and selective small molecule inhibitors of the histone methyltransferase EZH2

Sharad K. Verma(GlaxoSmithKline (United States)), Dash Dhanak(Springhouse), Dominic Suarez(GlaxoSmithKline (United States)), Alan P. Graves(GlaxoSmithKline (United States)), Mark Mellinger(GlaxoSmithKline (United Kingdom)), Michael T. McCabe(GlaxoSmithKline (United States)), Art Shu(GlaxoSmithKline (United States)), Louis V. LaFrance(Johnson & Johnson (United States)), Steven D. Knight(GlaxoSmithKline (United States)), Xinrong Tian(GlaxoSmithKline (United Kingdom)), James Brackley(GlaxoSmithKline (United States)), Stuart P. Romeril(GlaxoSmithKline (United States)), Céline Duquenne(GlaxoSmithKline (United Kingdom)), Peter J. Tummino(Intarcia Therapeutics (United States)), Elsie Diaz(Johnson & Johnson (United States)), Heidi Morgan-Ott(GlaxoSmithKline (United States)), D. Scherzer(GlaxoSmithKline (United States)), Ryan G. Kruger(Arysta LifeScience (France)), Neil W. Johnson(Brandywine Photonics (United States)), Joelle L. Burgess(GlaxoSmithKline (United States)), Caretha L. Creasy, Seth W. Grant(GlaxoSmithKline (United States)), William H. Miller(Clinical Innovations (United States)), K. A. NEWLANDER(South College), BaoChau Le(GlaxoSmithKline (United States)), Christine Thompson(GlaxoSmithKline (United Kingdom)), Charles F. McHugh(GlaxoSmithKline (United States))
Cancer Research
April 1, 2012
Cited by 1


Related Papers